Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Not yet recruiting 1Active not recruiting 1

Sponsor Class

NIH 1NETWORK 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Carcinoma, Non-Small-Cell Lung 53Breast Neoplasms 26Lung Neoplasms 21Triple Negative Breast Neoplasms 16Neoplasm Metastasis 16Pancreatic Neoplasms 15Neoplasms 15Stomach Neoplasms 14Colorectal Neoplasms 14Head and Neck Neoplasms 12Esophageal Neoplasms 12Esophageal Squamous Cell Carcinoma 11Uterine Cervical Neoplasms 10Squamous Cell Carcinoma of Head and Neck 10Small Cell Lung Carcinoma 10Rectal Neoplasms 9Ovarian Neoplasms 8Leukemia, Myeloid, Acute 8Recurrence 7Nasopharyngeal Carcinoma 7Glioblastoma 5Fallopian Tube Neoplasms 5Cholangiocarcinoma 5Urinary Bladder Neoplasms 4Sarcoma 4Oropharyngeal Neoplasms 4Mouth Neoplasms 4Lymphoma 4Endometrial Neoplasms 4Colonic Neoplasms 4

Interventions

trastuzumab biosimilar HLX02 2ribociclib 2pertuzumab 2Trastuzumab 2Taxes 2Specimen Handling 2Paclitaxel 2PF-05280014 2Ontruzant 2Ogivri 2Magnetic Resonance Spectroscopy 2Drug Therapy 2Docetaxel 22C4 antibody 2tucatinib 1exemestane 1durvalumab 1Surgical Procedures, Operative 1Radiotherapy, Intensity-Modulated 1Radiotherapy, Conformal 1Radiotherapy 1Radiation 1Mastectomy, Segmental 1Mastectomy 1Letrozole 1Immunoglobulin G 1High-Energy Shock Waves 1Genetic Testing 1Fulvestrant 1Fluorodeoxyglucose F18 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Anatomic Stage II Breast Cancer AJCC v8 × Drug Therapy × 1 year × Clear all
NCT07391774 2026-05-13

Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial

National Cancer Institute (NCI)

Phase 3 Not yet recruiting
1,978 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

NCT05710328 2026-05-05

Testing the Role of FDG-PET/CT to Predict Response to Therapy Prior to Surgery for HER2-positive Breast Cancer, The DIRECT Trial

Eastern Cooperative Oncology Group

Phase 2 Active not recruiting
235 enrolled
Breast

Anatomic Stage II Breast Cancer AJCC v8

Data powered by HemOnc (CC BY 4.0) Colophon âš¡